硝卡芥联合凝血酶治疗恶性血性胸水的临床观察  

Clinical observation of Nitrocaphane combined with Thromb in for malignant and bloody pleural effusion

作　　者：张传建[1] 刘化勇[1] 

机构地区：[1]临沂市人民医院肿瘤医院,临沂276000

出　　处：《齐鲁药事》2005年第4期247-249,共3页qilu pharmaceutical affairs

摘　　要：目的　观察硝卡芥联合凝血酶治疗恶性胸腔积液的临床疗效。方法　4 7例均为恶性血性胸腔积液患者,随机分为两组,2 4例胸腔注射硝卡芥、凝血酶、地塞米松者为观察组;2 3例注射凝血酶、地塞米松者为对照组。可做2～4次,5～7d一次。结果　观察组2 4例中,治疗1次者13例,2次以上者11例。对照组治疗1次者7例,2次以上者16例。总有效率观察组(CR +PR)19例(79 .1%),对照组为11例(4 7. 8%),两组相比具有显著差异,P <0 . 0 5。且生活质量(KPS评分)近期改善有明显差异,P <0 . 0 5。观察组缓解期明显延长。结论　硝卡芥联合凝血酶治疗恶性胸腔积液疗效高,毒副作用轻,可以提高患者的生活质量。Objective To observe the clinical efficacy of Nitrocaphane combined with Thrombin for malignant and bloody pleural effusion.Methods Fourty-seven patients were randomly divided into the observation group(group A) and control group(group B),they were malignant and bloody pleural effusion petients.24 patients were treated with Nitrocaphane combined with Thrombin and dexamethasone (group A).23 patients were treated with Thrombin and dexamethasone(group B).They were treated 2～4times and the intervening time was 5～7days.Results 13 cases were treated only one time and 11 cases were treated over two times in observation group.6 cases were treated only one time and 17 cases were treated over two times in control group.The overall response rates(CR+PR) were 19 cases(79.1%) in observation group and 11 cases(47.8%) in control group,the significance was evident(P<0.05).Quality of life(KPS) was improved in observation group and no change in control group.Release period was prolonged in observation group.Conclusion The study points out that Nitrocaphane combined with Thrombin for malignant and bloody pleural effusion can improve clinical efficacy and quality of life,reduce side effects and improve the quality of patients' life.

关 键 词：硝卡芥 凝血酶 恶性胸腔积液 疗效 

分 类 号：R969.4[医药卫生—药理学]